Eterna Therapeutics Stock (NASDAQ:ERNA)
Previous Close
$1.95
52W Range
$1.71 - $29.25
50D Avg
$2.47
200D Avg
$5.65
Market Cap
$14.06M
Avg Vol (3M)
$77.03K
Beta
6.80
Div Yield
-
ERNA Company Profile
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.